Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 288, Issue 5 51-5, 2005, Pages

  Yoshiji, Hitoshi ^a   Noguchi, Ryuichi ^a   Kuriyama, Shigeki ^b   Ikenaka, Yasuhide ^a   Yoshii, Junichi ^a   Yanase, Koji ^a   Namisaki, Tadashi ^a   Kitade, Mitsuteru ^a   Masaki, Tsutomu ^b   Fukui, Hiroshi ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b KAGAWA UNIVERSITY   (Japan)

Author keywords

Hepatic stellate cell; Platelet derived growth factor

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CELL MARKER; HYDROXYPROLINE; IMATINIB; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR BB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROCOLLAGEN; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; LIVER FIBROSIS; MITOGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; STATISTICAL SIGNIFICANCE; STELLATE CELL; SWINE;

ANIMALS; GENE EXPRESSION; HEPATOCYTES; LIVER CIRRHOSIS; MALE; PIPERAZINES; PYRIMIDINES; RATS; RATS, INBRED F344;

EID: 20244384873     PISSN: 01931857     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpgi.00420.2004     Document Type: Article

References (38)

1. Albanis E and Friedman SL. Hepatic fibrosis. Pathogenesis and principles of therapy. Clin Liver Dis 5: 315-334, 2001.
2. Befeler AS and Di Bisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 122: 1609-1619, 2002.
3. Beham-Schmid C, Apfelbeck U, Sill H, Tsybrovsky O, Hofler G, Haas OA, and Linkesch W. Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis. Blood 99: 381-383, 2002.
4. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, and Lydon NB. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295: 139-145, 2000.
5. Carroll M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon NB, Gilliland DG, and Druker BJ. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 90: 4947-4952, 1997.
6. Druker BJ and Lydon NB. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 105: 3-7, 2000.
7. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, and Sawyers CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344: 1031-1037, 2001.
8. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, and Lydon NB. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2: 561-566, 1996.
9. Friedman SL. Cytokines and fibrogenesis. Semin Liver Dis 19: 129-140, 1999.
10. Friedman SL. Liver fibrosis - from bench to bedside. J Hepatol 38 Suppl 1: S38-S53, 2003.
11. Hanada M, Feng J, and Hemmings BA. Structure, regulation and function of PKB/AKT - a major therapeutic target. Biochim Biophys Acta 1697: 3-16, 2004.
12. Heldin CH and Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79: 1283-1316, 1999.
13. Hwang RF, Yokoi K, Bucana CD, Tsan R, Killion JJ, Evans DB, and Fidler U. Inhibition of platelet-derived growth factor receptor phosphorylation by ST1571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. Clin Cancer Res 9: 6534-6544, 2003.
14. Iredale JP. Tissue inhibitors of metalloproteinases in liver fibrosis. Int J Biochem Cell Biol 29: 43-54, 1997.
15. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B, and Demetri GD. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344: 1052-1056, 2001.
16. Kinnman N, Francoz C, Barbu V, Wendum D, Rey C, Hultcrantz R, Poupon R, and Housset C. The myofibroblastic conversion of peribiliary fibrogenic cells distinct from hepatic stellate cells is stimulated by platelet-derived growth factor during liver fibrogenesis. Lab Invest 83: 163-173, 2003.
17. Kinnman N, Goria O, Wendum D, Gendron MC, Rey C, Poupon R, and Housset C. Hepatic stellate cell proliferation is an early platelet-derived growth factor-mediated cellular event in rat cholestatic liver injury. Lab Invest 81: 1709-1716, 2001.
18. Leung NW. Management of viral hepatitis C. J Gastroenterol Hepatol 17 Suppl: S146-S154, 2002.
19. Marra F, Gentilini A, Pinzani M, Choudhury GG, Parola M, Herbst H, Dianzani MU, Laffi G, Abboud HE, and Gentilini P. Phosphatidylinositol 3-kinase is required for platelet-derived growth factor's actions on hepatic stellate cells. Gastroenterology 112: 1297-1306, 1997.
20. McGary EC, Weber K, Mills L, Doucet M, Lewis V, Lev DC, Fidler IJ, and Bar-Eli M. Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. Clin Cancer Res 8: 3584-3591, 2002.
21. Okita K, Sakaida I, and Hino K. Current strategies for chemoprevention of hepatocellular carcinoma. Oncology 62 Suppl 1: 24-28, 2002.
22. Olaso E and Friedman SL. Molecular regulation of hepatic fibrogenesis. J Hepatol 29: 836-847, 1998.
23. Omori M, Evarts RP, Omori N, Hu Z, Marsden ER, and Thorgeirsson SS. Expression of α-fetoprotein and stem cell factor/c-kit system in bile duct-ligated young rats. Hepatology 25: 1115-1122, 1997.
24. Pinzani M and Marra F. Cytokine receptors and signaling in hepatic stellate cells. Semin Liver Dis 21: 397-416, 2001.
25. Pinzani M, Marra F, and Carloni V. Signal transduction in hepatic stellate cells. Liver 18: 2-13, 1998.
26. Pinzani M, Milani S, Grappone C, Weber FL Jr, Gentilini P, and Abboud HE. Expression of platelet-derived growth factor in a model of acute liver injury. Hepatology 19: 701-707, 1994.
27. Roskoski R Jr. ST1-571: an anticancer protein-tyrosine kinase inhibitor. Biochem Biophys Res Commun 309: 709-717, 2003.
28. Sakaida I, Hironaka K, Uchida K, Suzuki C, Kayano K, and Okita K. Fibrosis accelerates the development of enzyme-altered lesions in the rat liver. Hepatology 28: 1247-1252, 1998.
29. Sakata R, Ueno T, Nakamura T, Sakamoto M, Torimura T, and Sata M. Green tea polyphenol epigallocatechin-3-gallate inhibits platelet-derived growth factor-induced proliferation of human hepatic stellate cell line LI90. J Hepatol 40: 52-59, 2004.
30. Shimizu I, Ma YR, Mizobuchi Y, Liu F, Miura T, Nakai Y, Yasuda M, Shiba M, Horie T, Amagaya S, Kawada N, Hori H, and Ito S. Effects of Sho-saiko-to, a Japanese herbal medicine, on hepatic fibrosis in rats. Hepatology 29: 149-160, 1999.
31. Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, Kuroki T, Nishiguchi S, Sata M, Yamada G, Fujiyama S, Yoshida H, and Omata M. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 132: 517-524, 2000.
32. Wong L, Yamasaki G, Johnson RJ, and Friedman SL. Induction of β-platelet-derived growth factor receptor in rat hepatic lipocytes during cellular activation in vivo and in culture. J Clin Invest 94: 1563-1569, 1994.
33. Yoshiji H, Kuriyama S, Miyamoto Y, Thorgeirsson UP, Gomez DE, Kawata M, Yoshii J, Ikenaka Y, Noguchi R, Tsujinoue H, Nakatani T, Thorgeirsson SS, and Fukui H. Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model. Hepatologyl 32: 1248-1254, 2000.
34. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Hicklin DJ, Huber J, Nakatani T, Tsujinoue H, Yanase K, Imazu H, and Fukui H. Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma. Hepatology 35: 834-842, 2002.
35. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Hicklin DJ, Wu Y, Yanase K, Namisaki T, Yamazaki M, Tsujinoue H, Imazu H, Masaki T, and Fukui H. Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis. Gut 52: 1347-1354, 2003.
36. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, Tsujinoue H, and Fukui H. Angiotensin II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 34: 745-750, 2001.
37. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, Tsujinoue H, Yanase K, Namisaki T, Imazu H, and Fukui H. Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse. Hepatology 36: 850-860, 2002.
38. Yoshiji H, Yoshii J, Ikenaka Y, Noguchi R, Tsujinoue H, Nakatani T, Imazu H, Yanase K, Kuriyama S, and Fukui H. Inhibition of renin-angiotensin system attenuates liver enzyme-altered preneoplastic lesions and fibrosis development in rats. J Hepatol 37: 22-30, 2002.